Brief: Immunovia Q4 Revenue SEK 155 Thousand
21/02/2024 07:30
Feb 21 (Reuters) - Immunovia Q4 adjusted free cash flow SEK -28 million. * Q4 adjusted EPS SEK -1.08 * Q4 net income SEK -49 million
Recent news on Immunovia AB (publ)
See all newsBrief: Immunovia Publishes Data On Pancreasure In Hereditary, Familial High-Risk Individuals
Brief: Immunovia To Carry Out Rights Issue Of About SEK 63 Million
Sweden's Immunovia Q2 sales rise on PancreaSure test uptake
Brief: Immunovia Reports Q2 Operating Loss Of SEK 22.8 Million
Brief: PancreaSure Achieves 88% Sensitivity In Immunovia Study